Eli Lilly's Obesity Drug Tilzepatide Gets Approval in China
July 22, 2024 9:50 AM GMT+9 (some excerpts)
US pharmaceutical giant Eli Lilly(LY.N)On the 19th, it was announced in a social media post that the obesity treatment drug “tilzepatide” had obtained approval from the Chinese authorities. Danish counterpart Novo Nordisk in key markets(Novob.co)Competition with “Ugobi” becomes even more intense.
Ugobi was approved for sale in China in June.
No response has been obtained from Eli Lilly's spokesperson to a request for comment on the start date and supply volume of tilzepatide in China. This drug is an active ingredient in Eli Lilly's diabetes drug “Manjaro” and weight loss drug “Zepp Bound.” Manjaro is also approved for sale in China.
Ugobi was approved for sale in China in June.
No response has been obtained from Eli Lilly's spokesperson to a request for comment on the start date and supply volume of tilzepatide in China. This drug is an active ingredient in Eli Lilly's diabetes drug “Manjaro” and weight loss drug “Zepp Bound.” Manjaro is also approved for sale in China.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
masa_4 : Nevertheless, the impact on stock prices is slim![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")